12  CH and MPN

13 The definition of MPNs continues to evolve

14 Prevalence of JAK2 and CALR

• Prevalence of JAK2 to CALR in CH is ~19:1
• Prevalence of JAK2 to CALR in MPN is ~6:1
• Hypothesis: CALR and MPL mutations exclusivley mimimc TPO

15 Allelic burden along the spectrum from JAK2 CH to MPN

16 Factors that influence JAK2 acquistion, clonal expansion and clinical phenotype

• Germline

• Somatic

• Extrinsic

17 Extra-hematologic consequences of JAK2

18 IFN aplha clinical trial in JAK2-mutant CH

• Risk of progression of DNMT3A
• We need to look at the clinical trial patient samples